NasdaqCM - Nasdaq Real Time Price USD

ProQR Therapeutics N.V. (PRQR)

1.8300
-0.0800
(-4.19%)
At close: June 9 at 4:00:00 PM EDT
1.9285
+0.10
+(5.38%)
After hours: June 9 at 7:59:25 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
18,974
18,905
6,514
3,594
1,335
Operating Expense
52,187
49,377
41,304
68,753
58,545
Operating Income
-33,213
-30,472
-34,790
-65,159
-57,210
Net Non Operating Interest Income Expense
2,141
2,174
1,390
-5,021
-3,400
Other Income Expense
688
338
5,587
6,072
-72
Pretax Income
-30,384
-27,960
-27,813
-64,108
-60,682
Tax Provision
-200
-197
-78
96
117
Net Income Common Stockholders
-30,184
-27,763
-28,119
-64,424
-60,740
Diluted NI Available to Com Stockholders
-30,184
-27,763
-28,119
-64,424
-60,740
Basic EPS
-0.33
-0.32
-0.35
-0.90
-0.96
Diluted EPS
-0.33
-0.32
-0.35
-0.90
-0.96
Basic Average Shares
92,017.9370
86,086.4860
81,011.4380
71,641.3050
64,182.4920
Diluted Average Shares
92,017.9370
86,086.4860
81,011.4380
71,641.3050
64,182.4920
Total Operating Income as Reported
-33,213
-30,472
-31,859
-65,159
-57,210
Total Expenses
52,187
49,377
41,304
68,753
58,545
Net Income from Continuing & Discontinued Operation
-30,184
-27,763
-28,119
-64,424
-60,740
Normalized Income
-30,177.0461
-27,756.0490
-32,739.0980
-67,083.9300
-62,218.2500
Interest Income
--
3,251
2,593
106
5
Interest Expense
--
1,077
1,203
5,127
3,405
Net Interest Income
2,141
2,174
1,390
-5,021
-3,400
EBIT
-29,624
-26,883
-26,610
-58,981
-57,277
EBITDA
-26,876
-24,122
-24,097
-56,460
-54,948
Reconciled Depreciation
2,748
2,761
2,513
2,521
2,329
Net Income from Continuing Operation Net Minority Interest
-30,184
-27,763
-28,119
-64,424
-60,740
Total Unusual Items Excluding Goodwill
-7
-7
4,634
3,367
2,025
Total Unusual Items
-7
-7
4,634
3,367
2,025
Normalized EBITDA
-26,869
-24,115
-28,731
-59,827
-56,973
Tax Rate for Calcs
0
0
0
0.0002
0.0003
Tax Effect of Unusual Items
-0.0461
-0.0490
13.9020
707.0700
546.7500
12/31/2021 - 9/18/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARWR Arrowhead Pharmaceuticals, Inc.
16.57
-1.43%
 
WVE Wave Life Sciences Ltd.
7.05
-2.35%
 
KRRO Korro Bio, Inc.
14.85
+1.78%
 
LXEO Lexeo Therapeutics, Inc.
4.3800
+12.89%
 
ENTA Enanta Pharmaceuticals, Inc.
7.50
+0.40%
 
NGNE Neurogene Inc.
19.91
-8.80%
 
QURE uniQure N.V.
16.90
-2.14%
 
IFRX InflaRx N.V.
0.8500
+2.40%
 
XENE Xenon Pharmaceuticals Inc.
31.45
-0.60%
 
ADVM Adverum Biotechnologies, Inc.
2.9700
+4.95%